By Dr. Claus Feussner, Senior Vice President Development Service, Vetter

Company: Vetter

The biopharmaceutical industry is navigating heightened complexity driven by increased demand for biologics manufacturing, evolving regulations, supply chain pressure, expanding therapeutic approaches, and growing patient needs. New regulations such as Annex 1 and emerging drug modalities are also sparking change in how biopharma companies maintain compliance and protect the supply chain. Amid these trends, the right partnership can be a stabilizing force. It can keep organizations strong, growing, and delivering their promise to patients worldwide.

Service providers who take advantage of these emerging trends will advance industry success. This proactive approach will serve as a foundation for fostering dependable drug development and delivering life-enhancing medications worldwide.

Contract development and manufacturing organizations (CDMOs) are enhancing services and serving a more strategic role in the supply chain. They are helping to maintain reliability, innovation, and speed in drug delivery across clinical and commercial phases. We believe long-term trusted partnerships, technological advancements, workforce stability through talent retention, and high-quality services are cornerstones of sustainability and longevity. By going beyond a transactional relationship, we grow powerful strategic collaborations across the biopharma value chain.

Many of our customers initially partnered with us for aseptic fill–finish manufacturing and expanded the partnership over time to take advantage of more of our specialized clinical and commercial services. These trusted partnerships create the opportunity for us to collaborate with the company to solve issues, streamline processes, and prepare for potential future obstacles. We recommend sustainable secondary packaging and material options to our customers early in process development while providing specialized consultation for choosing the right device. It is important to establish packaging decisions early so customers can make informed choices that support strategic and efficient production.

Providing appropriate recommendations and putting our material resources to work starts with listening to our customers. It gives us the necessary information we need, so we can offer individual approaches to meet their evolving needs across the value chain. This leads to reliable partnerships that are stable, powerful, and long-lasting.

In the modern digital age, advanced technology supports corporate strategy. It also strengthens operations, when applied thoughtfully. Companies that stay up to date on the latest technology and understand how it improves business processes will increase stability and efficiency to support future success.

Artificial Intelligence (AI) and other technologies can add real value to enhance decision-making and reinforce reliable processes, quality, and efficiency when implemented with intention. Our AI applications focus on three areas: everyday efficiency, process transformation, and strategic differentiation. They help us simplify daily tasks, rethink and improve workflow efficiencies, and strengthen our corporate strategy.

Although they are powerful enablers, AI tools cannot think, decide or lead for themself. Their success relies on the human beings who operate them. We consider it our responsibility to our customers to be intentional when incorporating AI to enhance ongoing operations and processes. Our people-driven approach to AI relies on human accountability.

In practice, this means we integrate technologies such as Robotic Process Automation and AI tools such as Natural Language Generation into our corporate strategy to build resilience and enhance competitiveness. These features improve precision and reliability across our services. In the near future, we plan to apply AI tools to additional processes including predictive maintenance, remote services, and intelligent assistance systems to further increase operational efficiency.

In the highly regulated environment of the life science industry, there is no replacing human judgement, ethics or accountability. Even as we implement these tools, we keep people at the center.

Indeed, maintaining human-centric processes is a value throughout our business operations, even beyond responsible AI use. With increasing operational demands due to evolving patient needs and changing market requirements, service providers depend on attracting top talent to maintain process development and manufacturing excellence. However, talent shortages persist throughout the industry worldwide. To maintain high-quality services and meet evolving customer needs, it is not enough to hire well – we also prioritize fostering and retaining our talent.

Equipping our workforce with the skills for the industry’s trends and future is foundational to this effort. We have expanded our commitment to empowering the workforce of the future. To complement our existing Technical Training Center, we established a specialized Training Center for scientific professionals. This center features state-of-the-art laboratories, classrooms, and the latest pharmaceutical technology and equipment. It lays the foundation for our learning and development programs, which include real-world, hands-on lab practice and upskilling for employees. Both centers also feature training rooms for further education and collaborative work areas for self-organized learning. In the near future, Vetter will also offer an Augmented and Video Reality (VR/AR) environment for the implementation of digital learning. These in-house training initiatives equip our employees with cross-functional expertise, digital skills and other capabilities in updated production processes to set them up for success.

This approach keeps our workforce resilient and adaptable as we stay at the cutting edge of best practices. It also helps us to attract and retain a driven workforce that is adaptable and supports corporate growth. Our operational success is rooted in the skills, agility, and dedication of our people and our corporate commitment to continually developing these employees for future-role readiness. Further, we prioritize a positive culture enriched by efficiencies and supported by technology. This means we implement tech tools such as automation, digitalization and AI tools to support onboarding and process optimization. From skill development to well-being, our emphasis on a dynamic and supportive environment keeps our talent advancing and our operations reliable.

Successful drug product development and a possible later commercialization for a biopharma company heavily depends on efficient and precise aseptic fill and finish services. The manufacturing operations play a deliberate role, especially under the pressure of high regulations and tight timelines. As a specialized CDMO, we offer both clinical and commercial services to reduce risks and streamline transitions between processes.

The increasing development of complex modalities is bringing awareness to the importance of specialized manufacturing partners within the injectables sector. Due to evolving biologic molecules and new regulatory requirements, technology is continuing to change across the industry. Aseptic fill and finish services that are flexible, technically advanced and meet high quality standards are essential to address the evolving needs of pharma and biotech companies.

The transition from early- to late-stage clinical development is one of the most critical phases in a drug’s lifecycle. The process involves significantly scaling up production, collaborating with partners, and making strategic regulatory decisions. To navigate this stage, we take a structured, proactive approach to put our customer on the path to clinical success.

The success of life-enhancing therapies relies on early strategic planning and partner alignment. Providing clinical material for in-human trials in early-phase manufacturing is one example. With the volatility of the market and the challenge of securing funding, clinical development can be difficult for biopharma companies to navigate alone. A good partner will help a biopharma company to project and plan for this. Additional support capabilities often include conducting analytical studies, preparing and meeting regulatory requirements, and more to carry the product from molecule to therapy. Packaging decisions are also important in early-phase development to support compatibility. Our device assembly processes consider the primary packaging, product characteristics, and secondary packaging plans of the customer. Alignment of production processes across the supply chain to maintain compliance with regulatory guidelines is also essential to reach constancy and quality in drug development and delivery. We offer comprehensive fill and finish services that include producing clinical trial materials such as small clinical batches, optimizing scale-up, and providing packaging and shipping capabilities.

From clinical and commercial filling to device assembly and secondary packaging, we support our biopharma partners with flexible and holistic services. This comprehensive portfolio delivers high-quality drug products in a timely manner so the drug can succeed in the market and relieve patients worldwide.

Looking ahead, biopharma companies need strong partners to succeed. As the market shifts and the demand for advanced biologics grows, they need service providers that stay on top of the trends of long-lasting partnerships, enabling technologies and tools, talented workforces, and clinical and commercial service excellence to maintain a competitive edge.

The future biopharma industry will not be defined by technological advancements and global capacity alone. It will also be shaped by strategic collaborative partnerships across the supply chain. Biopharma companies and their trusted partners are committed to future success through a shared strategic vision, stable relationships, and a balanced integration of technology and talent investment. This foundation enables them to rely on services that ultimately strengthen confidence and resilience in drug delivery for generations to come.